Bill and Melinda Gates, co-chairs, the Gates Foundation 1As co-chairs of the Bill & Melinda Gates Foundation, Bill
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
PHARMA 40 2007
1
Bill and Melinda Gates, co-chairs, the Gates Foundation
As co-chairs of the Bill & Melinda Gates Foundation, Bill Foundation’s global health programme, said: ‘The
and Melinda Gates have control of a fund of $31.9 billion. pharmaceutical industry plays a huge role in improving
One of the foundation’s core missions is to tackle deadly global health, and we are proud to support several
diseases such as malaria and tuberculosis. With this kind public-private partnerships working with industry. The
of spending power and their determination to drive up pipeline of new drugs and vaccines for the developing
global healthcare provision, the Gates’ influence on the world is stronger than before.’
pharma industry is unquestionable.
Bill began his philanthropic efforts in earnest in 1994,
‘The Gates have largely abandoned their commercial when he created the William H Gates Foundation, which
ventures to run their foundation, which is dedicated to focused on global health. Three years later, he and Melinda
research aimed at eliminating serious infectious diseases,’ created the Gates Library Foundation, which worked to
commented one of our judges. ‘Their example has moved bring public access computers with internet connections
others with substantial wealth to follow their example. to public libraries in the US. The two groups merged in
hence they are a powerful force for good.’ 2000 to form the Bill & Melinda Gates Foundation.
The Gates meet with local, national, and international Joining Microsoft Corporation in 1987, Melinda oversaw
grantees and partners to further the foundation’s goal the development of many of Microsoft’s multimedia
of improving equity around the world. They also use products. In 1996, she retired from her position as general
their many public appearances to focus attention on manager of information products. Since then, she has
these issues. Dr Tachi Yamada, president of the Gates directed her energies towards the non-profit world.
|
14 WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net
Welcome to World Pharmaceutical Frontiers’ first Pharma 40 – a list of
the most influential people in the industry, as judged by industry experts.
The Pharma 40 has been for accuracy, but because the billion, but does their position Next year’s Pharma 40 will,
a great opportunity to top spot was such a surprise. at the top spot represent a I’m sure, make equally
evaluate the figures who Who would have thought shift in the balance of power? compelling reading. Until
have the biggest impact on philanthropists exert such Certainly, according to our then, do you think our judges
our industry – and to see the a massive influence on the judges, bigger does not mean have got it right? Is anyone
sheer scope of their different industry? Clearly, Bill and better. Pfizer CEO Jeffrey missing from the list?
influences. But when the votes Melinda Gates are no ordinary Kindler ranks 19th on the list, Give us your feedback on the
came in, we had to triple- philanthropists, controlling and only a handful of CEOs Pharma 40 on our website:
check our figures – not just as they do a pot of $31.9 crack the top 10. www.worldpharmaceuticals.net
1
11 Professor Rolf Krebs, scientist
Bill and Melinda Gates
Co-chairs, Bill & Melinda Gates Foundation 12 Roger L Williams, CEO, United States Pharmacopeia
13 David Brennan, CEO, AstraZeneca
14 Arthur Levinson, CEO, Genentech
2 Daniel Vasella
MD, chairman and CEO, Novartis 15 Jean-Pierre Garnier, CEO, GSK
16 Israel Makov, president and CEO, Teva
17 Marvin Carruthers, professor, University of Colorado
3 Andrew von Essenbach
Acting commissioner, US FDA 18 M Cass Wheeler, CEO, American Heart Association
19 Jeffrey Kindler, CEO, Pfizer
20 Sir Michael Rawlins, chairman, NICE
4 Craig C Mello
Professor, University of Massachusetts
21 Henri A Termeer, CEO, Genzyme
22 Dr M Venkateswarlu, drugs controller general of India
& Andrew Z Fire
Professor, Stanford School of Medicine
23 Frances M Visco, president, National Breast Cancer Coalition
24 Senator Charles E Grassley, chairman,
Senate Finance Committee
25 Dietmar Hopp, entrepreneur and co-founder, SAP
5 Thomas Lönngren
Executive director, EMEA
26 Tejendra Khanna, chairman, Ranbaxy
27 Eliot Spitzer, governor of New York
28 Tony Clement, minister of health, Canada
6 Craig Venter
Former CEO, Accelerys
29 Shao Mingli, commissioner of the State FDA, China
30 Nancy Pelosi, speaker, US House of Representatives
31 Anji Reddy, chairman, Dr Reddy’s Laboratories
7 Arthur Higgins
Chairman, Bayer Healthcare Executive
Committee
32 Michael J Fox, founder, Michael J Fox Foundation
33 H Fred Mickleson, chairman, National Board of Directors,
American Cancer Society
34 Bernard Poussot, president and vice chairman, Wyeth
35 Jean-François Dehecq, chairman and CEO, Sanofi Aventis
8 Christopher Lipinski
Ex-senior research fellow, Pfizer 36 Ronald D Luff, director of anatomic clinical trials,
Quest Diagnostics
37 Richard Reichman, William Bonnez and Robert Rose
9
University of Rochester
Bill Clinton
Founder, Clinton Foundation 38 Ranjit Shahani, president, Organisation of Pharmaceutical
Producers of India
39 Richard T Clark, CEO, Merck
10 CEO,
Ginger Graham
Amylin Pharmaceuticals
40 Pankaj Patel, chairman, Zydus Cadila
|
WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net 15
2 3
Daniel Vasella Andrew C von Eschenbach
Daniel Vasella earns second place in the Pharma 40 as CEO of Andrew C von Eschenbach, MD, was sworn in as the 20th
Novartis, one of the largest pharma companies in the world, commissioner of the US FDA in December 2006. He leads the US’s
generating sales of $37 billion in 2006. In charge of the Swiss giant premier consumer protection and health agency and, as such, holds
since 1996, Vasella should be used to appearing in such power lists; sway over regulated products that account for more than 20% of
three years ago, Time magazine named him as one of its 100 most consumer spending.
influential people of 2004.
As the former director of the National Cancer Institute (NCI),
Vasella graduated with an MD from the University of Bern in von Eschenbach is a nationally recognised urologic surgeon and
1979. After holding a number of medical positions in Switzerland, oncologist. His distinguished career as a leader in the fight against
he joined Sandoz Pharmaceuticals Corporation in the US in cancer spans nearly three decades. Himself a cancer survivor, von
1988, where he became a member of the Sandoz Group Executive Eschenbach has had a major impact on the fight against cancer,
Committee and CEO of Sandoz Pharma Ltd. which extends beyond the clinical and academic communities. He
is a founding member of C-Change and was president-elect of the
He has been the recipient of a number of awards, including the American Cancer Society.
Harvard Business School’s Alumni Achievement Award, the Appeal
of Conscience Award and the AJ Congress Humanitarian Award. Many organisations have recognised von Eschenbach for his
In 2002, he was awarded an honorary doctorate by the University accomplishments, including the American Medical Writers
of Basel. He has also been honoured with the Ordem Nacional Association, the American Urological Association, and the Uniformed
do Cruzeiro do Sul (Brazil) and holds the rank of Chevalier in Services University of Health Sciences. In 2006, he was named one of
the Ordre National de la Légion d’Honneur (France). Time magazine’s 100 most influential people.
Craig C Mello and Andrew Z Fire
Craig Mello and Andrew Fire were jointly awarded the Nobel Prize in
Physiology or Medicine in 2006 for their discovery of RNA interference – a
breakthrough which has revolutionised the the study of gene function. Global
4
pharma companies have been quick to exploit its ease of use, low cost and
adaptability to high-throughput applications.
Mello was previously a postdoctoral fellow at the Fred Hutchinson Cancer
Research Center in the laboratory of Dr James Priess. He joined the faculty of the
University of Massachusetts Medical School in 1994.
Fire conducted his initial work on gene silencing by double-stranded RNA at
the Carnegie Institution. In 1989, he became an adjunct professor in the Johns
Hopkins University department of biology and joined Stanford in 2003.
|
16 WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net
5 Thomas Lönngren
8 Christopher Lipinski
Thomas Lönngren was appointed executive director Dr Christopher Lipinski is best known as the author
of the European Medicines Agency (EMEA) in January of the Rule Of Five, a simple algorithm for predicting
2001. The EMEA is responsible for the scientific drug compounds likely to show oral activity. He is
evaluation of applications for European marketing currently a scientific adviser to Melior Discovery, a drug
authorisation for medicinal products – about one-third of the new repurposing startup. He was adjunct senior research fellow at the Pfizer
drugs introduced to the world market each year. Companies submit Global R&D Groton CT Laboratories until he retired in 2002.
one single marketing authorisation application to the EMEA for the A consultant on drug-like properties, he serves on many scientific
whole of Europe. advisory and journal editorial boards. In 2006, he received an honorary
Lönngren qualified as a pharmacist from the University of Uppsala in law degree from the University of Dundee, and he is winner of the 2006
1976, where he was a lecturer until 1978. He served with the Swedish Society for Biomolecular Sciences Achievement Award.
National Board of Health and Welfare from 1978 to 1990. From 1982 In 2005 he won the American Chemical Society’s E. B. Hershberg Award
to 1984 he acted as senior pharmaceutical consultant for the Swedish for Important Discoveries in Medicinally Active Substances and in
International Development Agency’s health cooperation programme 2004 won the the ACS Division of Medicinal Chemistry’s Division of
in Vietnam. In 1990, he was appointed director of operations, Swedish Medicinal Chemistry Award. He is responsible for over 225 published
Medical Products Agency, later becoming deputy director-general. articles and presentations and 17 issued US patents.
6 J Craig Venter
9 Bill Clinton
Our judges ranked Dr J Craig Venter high in the Bill Clinton is perhaps another surprising face to
Pharma 40 for his visionary contributions to genomic appear in our top 10, but as founder of the Clinton
research, which have secured his place as one of the Foundation, he heads an organisation which campaigns
Photo: © World Bank/Damian Milverton
leading scientists of the 21st century. He is the founder strongly on global health issues. And as a former
and president of the J Craig Venter Institute and the J Craig Venter president of the US, his public profile is second to none.
Science Foundation, and the founder of the Institute for Genomic After leaving the White House, Clinton founded the Clinton
Research. Research at the Venter Institute reflects his interest in Foundation, an organisation that campaigns on global health issues,
advancing the science of genomics and in applying genomic advances to with an emphasis on HIV/AIDS; economic empowerment; leadership
the world’s most vexing public health and environmental challenges. development and citizen service; and racial, ethnic and religious
In 1998, he became the first president of Celera Genomics, where reconciliation. Following the 2002 Barcelona AIDS Conference,
he sequenced the human genome using the whole genome shotgun he began the Clinton Foundation HIV/AIDS Initiative, which is
technique, new mathematical algorithms and new automated DNA currently bringing life-saving treatment to over a quarter of a
sequencing machines. million people around the world.
His many awards include the 2002 Gairdner Foundation International Like Bill and Melinda Gates, our judges believe Clinton’s high-profile
Award and the Ludwig Darmstaedter Prize. healthcare crusade is already changing the face of pharma.
7 Arthur J Higgins
10
Ginger Graham
Bayer Healthcare is another global pharma giant Although she is soon to step down as CEO of Amylin,
and Arthur J Higgins has been leading it since July Ginger Graham was picked by our judges for being a
2004. With a worldwide workforce of nearly 40,000 truly creative leader. Graham has been Amylin CEO
in the fields of pharmaceuticals, animal health, since June 2006 and president since September 2003.
consumer care and diabetes care, his influence on the global market She has served on the Audit Committee and the Nominating and
is undeniable. Governance Committee, and has also held various positions with the
Born in Scotland, Higgins studied at Scotland’s Strathclyde Guidant Corporation and Eli Lilly and Company.
University, where he gained a Bachelor of Science in biochemistry. She serves on the board of directors of the Pharmaceutical Research
He began his career in 1978 in the UK with Bristol-Myers. He has and Manufacturers of America, the California Healthcare Institute, the
subsequently worked for Sandoz, Fisons, Abbott Laboratories and Harvard Business School Health Advisory Board, the Harvard Business
Enzon Pharmaceuticals. School Dean’s Advisory Board, the Advisory Board for the Kellogg
He is a member of the board of directors of the Pharmaceutical Center for Executive Women, the Advisory Board for the California
Research and Manufacturers of America and a member of the Council on Science and Technology, and the University of California,
Council of the International Federation of Pharmaceutical San Diego Health Sciences Advisory Board. She has an MBA from
Manufacturers and Associations. Harvard University.
Have our judges got it right? Is anyone missing from the list? Give us your
feedback on the Pharma 40 on our website www.worldpharmaceuticals.net
|
WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net 17
11
11 Professor Rolf Krebs Genentech in 1980 as a senior approach for preparing DNA 21
21 Henri A Termeer,
During a career spanning scientist holding various chips and large amounts of DNA. CEO, Genzyme
35 years, Professor Krebs has positions until he became Henri A Termeer was appointed
served as president of the chairman and CEO in July CEO of one of the world’s
18
18 M Cass Wheeler, CEO,
European Federation 1995. Levinson was appointed foremost biotech companies,
American Heart Association
of Pharmaceutical Industries a member of the board of Genzyme Corporation, in
M Cass Wheeler has been
and Associations from 1996 to directors that same year and 1985. Under his leadership,
CEO of the one of the US’s
1998 and as president of the was named chairman of the Genzyme has grown into
largest campaigning health
International Federation of board in 1999. one of the world’s leading
groups since October 1997.
Pharmaceutical Manufacturers biotechnology companies.
Under his leadership, the
Association from 2000 to
15
15 Jean-Pierre Garnier, CEO, AHA merged its 56 individual
2002. He is responsible for the
GlaxoSmithKline state and metropolitan 22
22 Dr M Venkateswarlu, drugs
development of a large number
JP Garnier assumed this role in affiliates into 12 regional controller general of India
of pharmaceutical products,
January 2001 with the merger affiliates and adopted a As DCGI, Dr Venkateswarlu
has served on many advisory
of SmithKline Beecham and single corporate structure. controls access to the Indian
boards and committees, and has
contributed to over 30 books. Glaxo Wellcome. He joined market, which is seeing massive
SmithKline Beecham in growth and interest from major
1990 as president of its 19
19 Jeffrey Kindler, CEO, Pfizer pharma companies.
12
12 Roger L Williams, CEO, United
pharmaceutical business Jeffrey Kindler became chairman
States Pharmacopeia (USP) in North America and was and CEO of Pfizer, the
Roger L Williams, MD, has been chairman of pharmaceuticals world’s largest research-based 23
23 Frances M Visco, president,
the executive vice president and from 1994 until 1995. pharmaceutical company National Breast Cancer Coalition
CEO of the USP since April in 2006. In his previous Frances Visco is the first president
2000. He provides strategic role of vice chairman and of NBCC, and a member of its
leadership for USP under the 16
16 Israel Makov, president and general counsel, he has led board of directors and executive
direction of its Board of Trustees. CEO, Teva Pharmaceuticals Pfizer’s worldwide legal, committee. In 1993, President
He also serves as chairman Israel Makov has been the compliance, communications, Clinton appointed her as one
of the Council of Experts, president and CEO of Teva government relations, of three members of the
USP’s scientific body, which since April 2002. Makov is corporate citizenship, President’s Cancer Panel, and
continuously revises the USP one of the founders of the policy development and she was the first consumer to
and National Formulary. Israel National Nanotechnology global seciruty groups. chair the Integration Panel of
Initiative. He has also been the Department of Defense
a director of Bank Hapoalim Peer-Review Breast Cancer
13
13 David Brennan, CEO, since October 2002, and a 20
20 Sir Michael Rawlins, Research Program.
AstraZeneca director of Ramot at Tel Aviv chairman, National Institute for
David Brennan is an executive University since 2001. Clinical Excellence (NICE)
director of AstraZeneca plc, Sir Michael Rawlins has been 24
24 Senator Charles E
and a member of the executive chairman of NICE since its Grassley (Iowa)
board of the Pharmaceutical 17
17 Marvin Caruthers, University formation in 1999. He is also As chairman of the Senate
Research and Manufacturers of Colorado chairman of the Advisory Finance Committee, Grassley
of America. He is also honorary The methodologies that are Council on the Misuse of has considerable influence
board member of the US CEO currently used for chemically Drugs, an honorary professor over the shape and scope of
Roundtable on Cancer. synthesising DNA were at the London School of key quality-of-life issues,
originally developed in Hygiene and Tropical including Medicare and
Professor Caruthers’ laboratory Medicine, University of Medicaid, affecting US
14
14 Arthur Levinson, CEO, almost 20 years ago. His London, and emeritus citizens. He has also been
Genentech research has also pioneered professor at the University a major campaigner on
Arthur Levinson joined a two-step DNA synthesis of Newcastle upon Tyne. pharmaceutical reform.
Judging panel 1 2 3
1 Michael A Santoro
is an associate professor in
Pharma 40 candidates were the business environment
drawn from your suggestions department at the Rutgers
on our website as well as Business School in Newark,
nominations from pharma New Jersey in the US, and
industry experts. From a 4 5 6 a faculty member of the
shortlist, each judge ranked Rutgers Center for Global
the names independently Change and Governance.
and from their decisions we
compiled the final list. Here, 2 Agnes V Klein, MD, DPH
we profile our judges, with is director of the Centre
thanks to each of them. for the Evaluation of
|
18 WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net25
25 Dietmar Hopp, among pharma companies has health campaigning 37
37 Richard Reichman, MD,
German billionaire piqued and his influence on the organisations, for more William Bonnez, MD and
The co-founder of German industry is likely to grow in the than 30 years, serving as Robert Rose, PhD, University
software company SAP has forthcoming years. chair at the local and of Rochester
invested millions in biotech national levels, including Richard Reichman is
and sees the sector as one with chairman of the board of professor of medicine
30
30 Nancy Pelosi, speaker of the
great growth opportunities. the California Division. and of microbiology and
House of Representatives
immunology, William Bonnez
The first woman in US
is associate professor
26
26 Tejendra Khanna, history to lead a major party,
of medicine and Robert
chairman, Ranbaxy congresswoman Pelosi has
34
34 Bernard Poussot, president Rose is associate professor
Tejendra Khanna has been promised an agenda of driving
and vice-chairman of Wyeth of medicine and of
chairman of Ranbaxy reform in healthcare in her
Bernard Poussot was elected microbiology and immunology
Laboratories Ltd since 1999. role as speaker of the House
COO and to the Wyeth at the University of Rochester.
He is widely regarded as an of Representatives.
board of directors in January They are the inventors
expert in international trade
2007 and was elected president of a vaccine to prevent
and public administration.
31
31 Anji Reddy, chairman, and vice chairman in April human papillomaviruses,
Dr Reddy’s Laboratories 2006. He is responsible a type of cancer that kills
27
27 Eliot Spitzer, Under Anji Reddy’s for overseeing Wyeth more than 250,000 women
governor of New York chairmanship, Dr Reddy’s Pharmaceuticals, Wyeth around the world every year.
Spitzer’s nomination to this Labs has been credited with Consumer Healthcare and
list came in before his turning the Indian bulk drug Fort Dodge Animal Health.
appointment as governor industry from dependence 38
38 Ranjit Shahani, president,
of New York, while he was on imports in the mid-1980s Organisation of Pharmaceutical
still attorney general. His to self reliance in the mid-1990s producers of India (OPPI)
position reflects the influence and into the export-oriented Ranjit Shahani is vice chairman
35
35 Jean-François Dehecq,
he has had on the industry industry that it is today. and managing director,
chairman and CEO,
and for helping to develop Novartis India Limited.
Sanofi-Aventis
new disclosure policies He has been president of
32
32 Michael J Fox, actor Jean-François Dehecq was
in the pharmaceutical business. OPPI since 2001, and is
Michael J Fox was diagnosed selected for this list after he
chairman of INTERPAT in India.
with young-onset Parkinson’s created what is now one of
28
28 Tony Clement, minister Disease in 1991. Since 1998 the world’s largest drugmakers
of health, Canada he has committed himself to through an aggressive
39
39 Richard T Clark, CEO, Merck
There has been much focus on the campaign for increased takeover of Aventis.
Richard T Clark has held
Canada’s health system and the Parkinson’s research and the a broad range of operating
cost of drugs in the country. Michael J Fox Foundation and strategic positions during
Tony Clement’s authority over is dedicated to ensuring the his tenure with Merck, a
this area has been acknowledged development of a cure for world-leading research-driven
36
36 Ronald D Luff, Quest
in his ranking. Parkinson’s disease within pharmaceutical company.
Diagnostics
this decade.
Ronald D Luff, MD, is
29
29 Shao Mingli, commissioner director of anatomic
of the State FDA, China 33
33 H Fred Mickleson, chairman of pathology for Quest Diagnostics’ 40
40 Pankaj Patel, chairman,
Shao Mingli oversees the the National Board of Directors, Teterboro laboratory. He Zydus Cadila
standards set for the manufacture American Cancer Society also serves as clinical professor Pankaj Patel has guided Zydus
and approval of drugs to one Fred Mickelson has been an and medical director of the Cadila down a path of accelerated
of the world’s largest markets. active volunteer the American Program in Cytotechnology growth, from a Rs220 crore
Although access to this market Cancer Society, one of the at Thomas Jefferson University company to a Rs870 crore group
is limited, it is growing. Interest largest and most important in Philadelphia. with competence in healthcare.
Radiopharmaceuticals and Association of the British He is also chairman of leading provider of
Biotherapeutic Products in Pharmaceutical Industry Molecular Staging, a market intelligence to
the Biologics and Genetic and has more than 20 genomics and proteomics the pharmaceutical and
Therapies Directorate. Her years’ experience in the company serving academic healthcare industries.
special interests include healthcare industry, holding researchers and major
the appropriate design of a range of senior leadership pharmaceutical companies. 5 Simon Hammett
clinical trials and the various roles in the UK and is head of life sciences
and complex ethical issues internationally. He is the 4 Clive Savage at Deloitte and Touche,
attendant to the design and founder and president is director of corporate London.
conduct of clinical trials. of New Medicine Partners, communications, EMEA, at
an advisory firm assisting IMS Health. Operating in 6 James Drury
3 Dr Richard Barker pharmaceutical and more than 100 countries, James Drury is editor of
is director general of the biotechnology companies. IMS Health is the world’s World Pharmaceutical Frontiers.
|
WorldPharmaceuticalFrontiers www.worldpharmaceuticals.net 19You can also read
